DRKS00031154
Recruiting
Not Applicable
Circulating DNA for treatment and follow-up in squamous cell cancers
Asklepios Tumorzentrum Hamburg0 sites600 target enrollmentFebruary 22, 2023
Conditionssquamous cell cancers
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- squamous cell cancers
- Sponsor
- Asklepios Tumorzentrum Hamburg
- Enrollment
- 600
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histopathologically verified SCC
- •Eligible for curatively or palliatively intended treatment
- •\= 18 of years
- •Written and oral consent
Exclusion Criteria
- •Other cancer disease within 5 year of SCC diagnosis
- •Conditions that will contraindicate blood samples
- •Potential lack of compliance to standard FU program and study participation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Exploring the utility of circulating tumor DNA in neoadjuvant settingCTRI/2016/09/007308DEPARTMENT OF BIOTECHNOLOGY15
Completed
Not Applicable
Prospective Evaluation of Circulating Tumour DNA (ctDNA) as Molecular Monitoring Tool and Prognostic Biomarker in Resectable Pancreatic AdenocarcinomasC25Malignant neoplasm of pancreasDRKS00010992niversitätsklinikum Freiburg25
Terminated
Not Applicable
DETECTION Trial: Using blood tests to guide early treatment of relapse in early stage melanomaSkin CancerCancerMalignant neoplasm: skinISRCTN94991276Christie Hospital NHS Foundation Trust8
Recruiting
Not Applicable
Circulating tumor DNA for minimal residual disease in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant: a multi-center prospective study.Acute Myeloid Leukemia, Myelodysplastic SyndromesJPRN-UMIN000033003Kanto Study Group for Cell Therapy70
Completed
Not Applicable
ctDNA as a Biomarker for Treatment Response in HNSCCCarcinoma, Squamous Cell of Head and NeckNCT03540563The Netherlands Cancer Institute70